1. Opportunity Analysis and Industry Forecast, 2016-2023 Nonalcoholic Steatohepatitis (NASH) Market Global Opportunity Analysis and Industry Forecast, 2017-2023

2. The global market is expected to garner $1.6 billion by 2020, registering a CAGR of 25.6% during the period 2014-2020. The high prevalence of Type II diabetes and obesity, which lead to NASH and other nonalcoholic fatty liver diseases (NAFLD), would boost market growth. North America's heightened focus of NASH research has resulted in its accounting for nearly half of the global market. It is also the region with the maximum occurrences of NASH and other nonalcoholic fatty liver diseases. Europe ranks second in terms of the prevalence of NASH. The number of patients living with the diabetes worldwide is expected to soar from 371 million in 2012 to 552 million by 2030. This suggests that by 2030, there will be 3 new cases of diabetes every 10 seconds. "The rampant growth of diabetes and obesity has prompted pharmaceutical manufacturers to seek out novel pharmaceutical solutions to tap promising potential in NASH," states AMR analyst Roshan Deshmukh. "Instrumental initiatives and increasing clinical trials for the development of novel NASH therapeutics will steer its faster commercialization," adds the analyst. Introduction of Nonalcoholic Steatohepatitis (NASH) Market

3. Scope ofthe Report Key Benefits Key Audiences Introduction of Nonalcoholic Steatohepatitis (NASH) Market

4. Key Benefits 1.Various opportunities for non alcoholic fatty liver disease therapeutics present in developed as well as developing economies are thoroughly assessed. 2.Substitute treatments and their potential impact on NASH therapeutics are strategically quantified in the report. 3.Opportunities from a business perspective latent in the Asia-Pacific region are brought to light. 4.Market dimensions of diagnostic techniques used in NASH monitoring provide a clear outline of the NASH therapeutics research market 5.Geography-wise segmentation of clinical trials is conducted to provide strategic intelligence to the stakeholder. 6.Drivers and factors limiting market expansion are studied in detail. Click to Access Full Summary of Non-alcoholic Steatohepatitis MarketNon-alcoholic Steatohepatitis Market

5. Table of Content (TOC) Chapter 1: Introduction Chapter 2: Executive Summary Chapter 3: Market Overview Chapter 4: Market Beyond: What To Expect By 2025 Chapter 5: Global Nonalcoholic Steatohepatitis Market By Drug Types Chapter 6: Global Nonalcoholic Steatohepatitis Market (Pipeline Drug Analysis)by Geography, 2013-2020 Chapter 8. Company Profiles

6. Segments Nonalcoholic Steatohepatitis (NASH) Market

7. Segments Nonalcoholic Steatohepatitis (NASH) Market Therapeutics GFT505 Obeticholic Acid (INT- 747) Simtuzumab and Liraglutide (Victoza) Vitamin E Pioglitazo ne Placebo

8. Company Profiles Ceramic Matrix Composites Market 1. Genfit 2. Gilead Science 3. Novo Nordisk 4. Intercepts Pharmaceuticals 5. Enzo Biochem, Inc. 6. Raptor Pharmaceutical Corp.

9. Follow Us On Thank You! For More Details Do Enquiry https://www.alliedmarketresearch.com/nonalcoholic-steatohepatitis-NASH-market Thank You Ceramic Matrix Composites Market